logo
Why over 15 million born between 2008–2017 may develop gastric cancer in their lifetime; Study makes alarming prediction

Why over 15 million born between 2008–2017 may develop gastric cancer in their lifetime; Study makes alarming prediction

Time of India5 days ago
A global study warns of a potential surge in gastric cancer cases. Millions born between 2008 and 2017 are at risk. India may have the second-highest number of cases after China. Helicobacter pylori infection is a major cause. Prevention through screening and treatment is crucial. Africa could see a significant rise without intervention. Investment in prevention is essential.
Tired of too many ads?
Remove Ads
What Causes Gastric Cancer?
Tired of too many ads?
Remove Ads
Can It Be Prevented?
Concern for Africa Too
A new global study has warned that more than 15 million people worldwide, born between 2008 and 2017, could develop gastric cancer at some point in their lives. According to the PTI report, India is likely to contribute the second highest number of these cases, after China.The study, published in the journal Nature Medicine, shows that around two-thirds of these projected cases will be in Asia, followed by the Americas and Africa.Researchers from the International Agency for Research on Cancer (IARC), a part of the World Health Organisation (WHO), analysed cancer data from 185 countries using the GLOBOCAN 2022 database. They combined this with death rate estimates from the United Nations."Globally, 15.6 million lifetime gastric cancer cases are expected within these birth cohorts, 76% of which are linked to Helicobacter pylori," the study said, as quoted by PTI.The main cause is believed to be a long-term infection from Helicobacter pylori, a common bacteria found in the stomach. The bacteria is known to cause inflammation that may lead to stomach ulcers and cancer. Gastric cancer is currently the fifth leading cause of cancer deaths in the world.The study projected that 10.6 million of the total future cases will happen in Asia, with India and China together accounting for 6.5 million. If no action is taken, India alone may see around 16.5 lakh (1.65 million) new cases of gastric cancer.Yes. The study said screening and treating Helicobacter pylori infections can significantly reduce cases. If proper steps are taken, up to 75% of future gastric cancer cases could be prevented.The researchers added that rising cases in young people and a growing elderly population might reverse the recent progress made in reducing stomach cancer cases globally.Although sub-Saharan Africa currently has a lower number of gastric cancer cases, the report warned that the region could see a sixfold rise in the future if preventive measures are not introduced.The authors called for more investment in population-level prevention, including early testing, public awareness, and access to treatment for infections that cause cancer.Inputs from PTI
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Naveen Patnaik returns to Odisha after 21 days after spine surgery in Mumbai
Naveen Patnaik returns to Odisha after 21 days after spine surgery in Mumbai

Hindustan Times

time16 hours ago

  • Hindustan Times

Naveen Patnaik returns to Odisha after 21 days after spine surgery in Mumbai

Biju Janata Dal (BJD) president Naveen Patnaik on Saturday returned to Bhubaneswar after fully recovering from his spine surgery for cervical arthritis in Mumbai. Patnaik had left for Mumbai on June 20 and underwent spine surgery for cervical arthritis.(PTI File) Patnaik's special flight landed at the Biju Patnaik International Airport at about 2 pm. He returned to Odisha after 21 days, said BJD senior vice president Debi Prasad Mishra. The former five-time chief minister of Odisha was accorded a ceremonial welcome by the party men and women, who gathered at the airport since morning. The Jai Jagannath slogan rented the air as Patnaik stepped out of the airport. Holding placards and BJD flags, thousands of people stood on both sides of the road leading from the airport to Naveen Niwas, the residence of Patnaik, to welcome and greet their leader. He waved to the people at the airport. Patnaik, the Leader of the Opposition in Odisha Assembly, had left for Mumbai on June 20 and underwent spine surgery for cervical arthritis at Kokilaben Dhirubhai Ambani Hospital in Mumbai on June 22. He was shifted to a private room from the ICU after being kept under observation for two days and was discharged from the hospital on July 7. The surgery was conducted by Dr S Rajasekaran, an orthopaedic surgeon and chairman of Ganga Medical Center and Hospitals in Coimbatore. In Patnaik's absence, the BJD's 15-member committee led by vice-president Debi Mishra was looking after party affairs in the state.

Facial, speech problems among after-effects of mucormycosis post recovery: ICMR study
Facial, speech problems among after-effects of mucormycosis post recovery: ICMR study

The Print

time18 hours ago

  • The Print

Facial, speech problems among after-effects of mucormycosis post recovery: ICMR study

Published last month in Clinical Microbiology and Infection, a leading microbiology journal, the study found that 14.7 per cent of 686 hospitalised mucormycosis patients died within a year, with most deaths occurring during initial hospitalisation. There was an uptick in cases of mucormycosis, a rare infection also known as 'Black Fungus', during the COVID-19 pandemic. New Delhi, Jul 12 (PTI) People who suffered from mucormycosis and recovered continue to battle long-term health effects of the fungal infection, such as facial disfigurement and speech difficulty, found an ICMR study. Critical predictors of poor survival included involvement of the brain or eyes, intensive care admission, poor glycaemic control, and comorbid conditions. Conversely, patients who received both surgical treatment and combination antifungal therapy (particularly Amphotericin-B formulations with Posaconazole) had significantly higher survival rates, said Dr Rizwan Suliankatchi Abdulkader, from ICMR's National Institute of Epidemiology (NIE), the lead author of the study. 'But survivors often faced disfigurement and psychological distress, with more than 70 per cent reporting at least one clinical sequela (complication or disability) and a substantial proportion experiencing loss of employment,' Rizwan said. 'These are not abstract complications. Facial disfigurement, impaired speech, anxiety, and loss of livelihood are lived realities for many survivors. It is time for India to move beyond life-saving interventions and focus on life-restoring systems of care, including mental health support and rehabilitation,' he said. Led by Rizwan and the All-India Mucormycosis Consortium, the study assessed survival, treatment outcomes, and post-recovery quality of life among hospitalised patients in India. This large-scale study, covering 686 patients from 26 tertiary hospitals across the country, is the first of its kind to offer long-term, prospective data on this critical public health concern. As a part of the study, 686 patients who had contracted mucormycosis between March and July 2021 were followed up for one year. Of the 686, 80 per cent (549) also had COVID-19. The prevalence of mucormycosis varies significantly, from 0.01 to 2 cases per million in developed countries to 140 cases per million in India and similar nations, with incidence approximately 80 times higher in India. Despite advances in medical care, mucormycosis remains a highly lethal and debilitating condition. 'This study reinforces the pressing need to ensure access to timely diagnosis, surgical interventions, and combination antifungal therapy in all parts of India,' said Dr Manoj Murhekar, Director of Chennai-based ICMR-NIE. 'We cannot overstate how essential high-quality, multidisciplinary care is for patients battling mucormycosis, especially given the irreversible complications they face if treatment is delayed,' said Murhekar, a senior author of the study. Spanning the length and breadth of India, the study involved institutions from nearly every region, capturing a diverse and realistic picture of mucormycosis management in both urban and rural populations. Rizwan stressed, 'This is not just a story of numbers. Behind every data point is a person who struggled with pain, disfigurement, and long-term disability. Our duty as clinicians and public health professionals is to reduce not just mortality but also the suffering that comes with survival. 'India has a disproportionately high burden of this disease. Our health systems must be better prepared.' The research comes at a time when India is still grappling with the long-term fallout of the COVID-19 pandemic, during which mucormycosis surged dramatically. As the global community turns its attention to pandemic preparedness and health system resilience, the study serves as a sobering reminder of the challenges posed by neglected fungal diseases. 'We hope our findings will serve as a call to action for policymakers, hospital administrators, and clinicians. Mucormycosis is not just a complication of COVID-19. It is a disease that demands long-term clinical attention, public health surveillance, and above all, compassion in care,' Rizwan said. PTI PLB SKY SKY This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store